Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712477 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function
A Phase 4 study, sponsored by Michigan State University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT01712477: Clinical Trial Phase 4 study, sponsored by Michigan State University.
NCT01712477 is a Phase 4 study that was terminated before completion, run by Michigan State University. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01712477, a Phase 4 study, was terminated before completion, sponsored by Michigan State University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a prospective randomized controlled pilot study in traumatic brain injury (TBI) patients who are sedated with either propofol or midazolam to compare the cytokine response and neuropsychological outcomes with and without elevated blood alcohol levels. Sedation is part of the standard treatment in patients with a TBI and has been proposed as a neuroprotective intervention in head-injured patients. Sedative regimens, such as midazolam and propofol, are not standardized and it is unclear whether sedation has a significant impact on recovery and outcome. A review of propofol versus midazolam in mechanically ventilated patients shows evidence that both provide effective sedation but there is lack of data to support one sedative over the other. Cytokines are released in response to tissue injury and act to generate a variety of physiologic responses. The cytokine elevation has been correlated with the extent of tissue injury. This study will compare the cytokine distribution patterns at specific posttraumatic time points in patients with a TBI sedated with either propofol or midazolam. Additional analysis will compare the cytokine response in patients whom had elevated blood alcohol levels with those with normal levels. Neuropsychological testing will also be performed to determine the extent of brain injury and recovery.
Primary Outcome
Extent of functional deficits from underlying traumatic brain injury
Interventions
- DRUG Intravenous sedation using propofol
- DRUG Intravenous sedation with midazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-12 |
| Phase | Phase 4 |
Why NCT01712477 stopped before completion
NCT01712477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Intravenous sedation using propofol is the first listed.
NCT01712477 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01712477 about?
NCT01712477 is a clinical study titled "A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function". This is a prospective randomized controlled pilot study in traumatic brain injury (TBI) patients who are sedated with either propofol or midazolam to compare the cytokine response and neuropsychological outcomes with and without elevated blood alcohol levels. Sedation is part of the standard treatm...
What is the current status of trial NCT01712477?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2011-11. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01712477?
The interventions under investigation include: Intravenous sedation using propofol (DRUG), Intravenous sedation with midazolam (DRUG).
Who is sponsoring clinical trial NCT01712477?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01712477's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia